Ocera Therapeutics fka OCRX

[DewDiligence]

OCRX had $51.2M at 12/31/14; no changes in clinical guidance:

http://finance.yahoo.com/news/ocera-reports-fourth-quarter-full-200100449.html

"We are nearing full capacity in our STOP-HE study with 94 sites activated across North America and Europe. We believe that we are on-track to complete enrollment by approximately the end of 2015, assuming that enrollment outside of the U.S. progresses at a rate that is comparable to enrollment in the U.S. We will update this projection after a planned interim analysis, which we now expect will occur by the end of the first quarter of 2015.”

CC at 4:30pm ET.